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ORIGINAL ARTICLE
Estimating the Future Impact of a Multi-Pronged
Intervention Strategy on Ocular Disease Sequelae
Caused by Trachoma: A Modeling Study
Manoj Gambhir1, Nicholas C. Grassly2,3, Matthew J. Burton4, Anthony W. Solomon4,
Hugh R. Taylor5, David C. Mabey4, Isobel M. Blake2,3, and Marı´a-Gloria Basa´n˜ez2
1Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia,
2Department of Infectious Disease Epidemiology, Imperial College London, London, UK, 3MRC Centre for
Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London,
London, UK, 4Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of
Hygiene & Tropical Medicine, London, UK, and 5Indigenous Eye Health Unit, Melbourne School of Population
Health, The University of Melbourne, East Melbourne, Victoria, Australia
ABSTRACT
Purpose: Trachoma control programs are underway in endemic regions worldwide. They are based on the SAFE
strategy (Surgery for trichiasis, Antibiotic distribution, Facial cleanliness, and Environmental improvement).
Although much is known about the effect of community-wide treatment with antibiotics on the prevalence of
Chlamydia trachomatis, the impact of the SAFE strategy on severe ocular disease sequelae (the main focus of the
Global Elimination of blinding Trachoma by 2020 program) remains largely unknown.
Methods: We use a mathematical model to explore the impact of each of the components of the SAFE strategy,
individually and together, on disease sequelae, arising from repeat infection and subsequent conjunctival
scarring. We ask whether two elimination goals, to reduce the prevalence of trachomatous trichiasis to 1 per
1000 persons, and the incidence of corneal opacity to 1 per 10,000 persons per annum, are achievable, and which
combinations of interventions have the greatest impact on these indicators.
Results: In high prevalence communities (here,420% infection of children aged 1–9 years), a combination of
efforts is needed to bring down sustainably the prevalence and incidence of ocular disease sequelae.
Conclusion: The mass delivery of antibiotics is highly beneficial for the clearance of infection, inflammation and
prevention of subsequent scarring, but needs to be supplemented with sustained reductions in transmission
and surgery to consider realistically the elimination of blindness by the year 2020.
Keywords: Blindness, Chlamydia trachomatis, elimination program, mathematical modeling, ocular sequelae
INTRODUCTION
Trachoma remains the world’s leading infectious
cause of blindness. In 2003, the World Health
Organization (WHO) estimated that 84 million
people had active disease (an inflammatory conjunc-
tivitis) that could lead to visual impairment, and that
7.6 million were severely visually impaired or blind as
a result of trachoma.1 Recently revised estimates have
halved the number of people with active trachoma,
probably due to the collection of more accurate data
since the introduction of the SAFE strategy (Surgery
for trichiasis, Antibiotic treatment of the causative
bacteria Chlamydia trachomatis, Facial cleanliness, and
Environmental improvement),2 the success of SAFE
implementation, and socioeconomic improvements in
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endemic areas.3 Yet, the number of people with
trichiasis (inward turning of eyelashes causing cor-
neal damage that will ultimately lead to blindness) is
currently about 8.2 million.3
The WHO’s simplified grading scheme4 discrimin-
ates follicular and inflammatory trachoma (TF and TI,
respectively). With repeated ocular chlamydial infec-
tion, episodes of inflammation lead to a scarring
immunopathological response, defined as trachoma-
tous scarring (TS).4 Further inflammation leads to
worsening of scarring that may turn the eyelid inward
and cause eyelashes to abrade the corneal surface
(trachomatous trichiasis, TT). If trichiasis is not
treated through surgical intervention, the eye may
become irreversibly damaged leading to corneal
opacity (CO) and eventually blindness.
Mass drug administration (MDA) programs, using
the antibiotic azithromycin, are part of the SAFE
strategy (the ‘‘A’’ component). The International
Trachoma Initiative (ITI) estimates that by 2015 MDA
programs will be active in 42 countries.5 Recently,
the London Declaration on Neglected Tropical
Diseases (endorsed on 30 January 2012), pledged to
support efforts to help eliminate blinding trachoma by
the year 2020.6 Because the time between the admin-
istration of treatment and its observed effects on
disease (and, in particular, trichiasis and CO) can be
very long, mathematical models can provide valuable
tools for predicting the long-term effects of treatment
and for assessing the feasibility of the 2020 goals. In
previous papers,7 we have shown that relatively
simple mathematical models reproduce adequately
many of the qualitative and quantitative patterns of
infection and disease observed in trachoma-endemic
communities prior to the introduction of MDA.
This paper investigates the effects of perturbing the
model through simulated treatment schedules to
ascertain (1) what effect these control interventions
might have on ocular disease, (2) whether the Global
Elimination of blinding Trachoma by 2020 (GET2020)
program goals are achievable, and (3) how long these
goals might take to achieve.
MATERIALS AND METHODS
Since the goals set by the WHO GET2020 alliance
primarily concern the elimination of prevalent cases
of TT (and, formerly, incident cases of CO), as well as
a reduction in the prevalence of active trachoma (TF,
TI),8 it was necessary to construct a mathematical
model that explicitly included the progress of indi-
viduals to such disease sequelae.
The model presented by Gambhir and co-authors,7
fitted to age-stratified prevalence data of TS and TT for
the high prevalence setting of Kongwa, Tanzania,
described by West and colleagues,9 was used as the
basis from which to investigate the treatment
schedules explored in this paper. Details of the model
structure and the values of the parameters are given in
the Supplemental Appendix (available online only).
The model used here is similar in structure to that
published by Lietman and co-workers,10 and is based
on the simple susceptible-infected-susceptible frame-
work; here, however, the infection transmission mech-
anism is simplified to allow for an additional model
feature, namely the path individuals take to the
development of disease sequelae. We considered a
treatment naive high-prevalence setting to be a reliable
source of data for the prevalence of disease sequelae
since in such a setting the influence of environmental
or socioeconomic secular trends will have been min-
imal, and it is reasonable to assume that infection
dynamics were at equilibrium, allowing us to clearly
associate infection transmission with disease sequelae.
Using estimated transmission parameters from this
high prevalence setting (420% infection of children
aged 1–9 years), we simulated the administration of
multiple antibiotic annual treatment rounds to popu-
lations whose initial infection prevalence level was
high. We examined the impact of MDA alone, and a
combination of surgery, MDA and ‘‘transmission
reduction,’’ on each of the disease sequelae prevalence
levels, with host age and time, and the impact of these
interventions on the incidence of severe disease
sequelae. We refer to the third of the interventions
we tested as ‘‘transmission reduction’’ rather than
F&E since the effectiveness of F&E is not well
understood and we wanted to prevent readers from
conflating our simulated intervention with F&E. It is
likely that F&E (and, indeed, Water, Sanitation and
Hygiene; WASH) interventions would be modeled as
‘‘transmission reduction,’’ but the disease modeling
community awaits further evidence before making
this link more explicit.
Model and Assumptions
The mathematical framework of our model has
previously been described in detail,7 its prototype
having been presented by Gambhir and co-authors.
Briefly, the model is based on the process of ocular
reinfection of individuals with C. trachomatis as they
come into contact with others who are infected.
Progressive conjunctival fibrosis/scarring (TS) is
believed to be initially caused by recurrent C.
trachomatis infection. However in the late stages of
the disease, other stimuli such as non-chlamydial
bacterial infection, may also contribute to this inflam-
matory-cicatricial process.11 Members of the popula-
tion eventually accumulate threshold numbers of
infection episodes, and these thresholds are inter-
preted as points beyond which individuals show
signs of the disease sequelae TS and TT. The third, and
more severe disease sequela, CO, has a different
Impact of Treatment on Trachoma Sequelae 395
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etiology, which we model by assuming that once
individuals show signs of TT, mechanical damage of
the cornea will gradually cause them to progress to
CO, regardless of whether they continue to be infected
(Figure 1).
The rate of recovery of individuals from an episode
of infection increases with age,12 and the model
includes this more rapid recovery by postulating its
cause as the increasingly rapid clearance of each
successive infection.13 Additionally, the infectivity of
individuals is assumed to be proportional to the
bacterial infection load they carry and this value
drops with age, which is likely to be another conse-
quence of acquired immunity.14,15 Model populations
were parameterized by fitting the model to
endemic infection and disease sequelae prevalence
data from Kongwa, Tanzania. This model was
also found to exhibit disease sequelae incidence
rates that closely matched those published for this
district.16 Thus calibrated to the disease sequelae
‘‘steady-state,’’ we had a model that could be used to
simulate control interventions. Mathematical details
of the model are presented in the Supplemental
Appendix.
Simulation of the Interventions Individually
and Together
We first ran the model for a 200-year equilibration
period to ensure a steady state was reached. We
simulated control scenarios based on the transmission
and disease parameters estimated from fitting the
model to a high prevalence setting at baseline
(Kongwa district, Tanzania7,9). Each intervention
component of the full strategy was simulated at a
high, medium or low intensity of effort (as detailed in
Table 1). Antibiotic treatment (A), was simulated by
shifting a proportion of the population in the infected
classes to the closest susceptible classes according to
an antibiotic efficacy of 95%,17 and a therapeutic
coverage level equal to 86% of the total population,
which was the level achieved by the first MDA round
in the high prevalence field study in Kongwa.9 At the
time of treatment, a population fraction given by
efficacy coverage had its bacterial carriage effectively
reduced to zero. Each MDA round was conducted in
successive years (and each set of three MDA rounds
was conducted in successive 3-year periods). The
simulation results were examined to determine the
effect of antibiotic treatment on age-dependent preva-
lence and incidence levels of disease sequelae over the
whole population. The ‘‘transmission reduction’’
intervention was simulated as an annual linear
decrease in the transmission rate over such a period
that the final transmission rate was 10% of its initial
value (i.e. a high-endemicity setting had been trans-
formed into a low-endemicity one). The rates of
decrease were chosen so as to achieve this decline in
transmission in 10, 20 or 30 years. The slowest-acting
of the ‘‘transmission reduction’’ interventions might
be interpreted as the rate associated with steady
economic development and the resulting environ-
mental improvement, an example of which occurred
in the Gambia between the mid-1980s and the mid-
1990s without concerted intervention.18 The provision
of surgery (S) for TT was simulated as a decrease in
the number of cases of TT over time at a rate such that,
from the onset of community surgery, the average
amount of time an individual spends with TT would
be 2, 5 or 10 years (ie, mean residence time in the TT
disease state is 2, 5 or 10 years, the mid value of which
is in line with current WHO guidelines1). Note that,
while the population to whom surgery is provided no
longer suffer from TT, they are still subject to the rest
of the infection and recovery dynamics in the model.
So, transmission of infection across the population is
not affected by surgery. When these three interven-
tions were implemented together (in pairs, or all three
at once), the intensities of the interventions were
combined like-with-like, so that interventions were
implemented at a low level for all three component
interventions (i.e. low S + low A + low ‘‘transmission
reduction’’). All seven possible intervention combin-
ations are detailed in Table 2. The time taken to
achieve the elimination or control goals was estimated
by focusing on the two goals relating to the elimin-
ation of blinding trachoma; (1) reduction in the
prevalence of TT to 1 case per 1000 persons, and
(2) reduction in the number of incident cases of CO to
51 per 10,000 persons per annum,8,19 a previously
codified goal for elimination, although this is now no
longer a formal target due to the difficulty in
estimating CO incidence in an endemic area. Life
FIGURE 1. Trachoma disease model diagram. Compartmental
disease model based on the ladder of infection framework of
Gambhir and colleagues7 with an extension to take into account
development of corneal opacities (CO) from the population of
those who previously developed trachomatous scarring (TS)
and then trichiasis (TT). The disease states TS and TT are
developed through repeat infection, but development of CO is
not linked to further infection and occurs at a constant rate as a
consequence of mechanical corneal damage incurred by those
with TT (see Supplemental Appendix for model parameters).
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table estimates from the WHO for the year 2001 were
used in the model for the age-specific death rates and
the overall population birth rate for Tanzania.20
Table S1 from the Supplemental Appendix sum-
marizes the variables and parameters of the model,
provides their values when these were chosen from
previous work or set to mimic different endemicity
levels, and indicates which parameters were esti-
mated by fitting the model to the data.
We also calculated the time course of the preva-
lence of TS, TT and CO and the incidence of CO for
each of the interventions. Each of the interventions
was implemented in populations that were initially in
a high prevalence state for trachoma infection (420%
infection prevalence in children 1–9 years21). The
reason that we did not investigate the effect of these
interventions on sequelae levels in medium- and low-
endemicity settings (10–20%, or 510% infection
TABLE 2. Global Elimination of blinding Trachoma by 2020 (GET2020) program goals and the implementation of components of the
full intervention strategy individually and in concert. Each component of the full intervention strategy is implemented at a low,
medium or high intensity, corresponding to the schedules detailed in Table 1. Outcome measures are stated here such that a value of
1.0 represents achievement of the GET2020 goals. The dark-shaded cells are those in which the GET2020 goals have been achieved and
cells that are light-shaded correspond to schedules in which the goal is almost achieved (i.e. within 100% of the goal).
Prevalence of TT post-intervention
(cases per 1000 persons)
Incidence of CO post-intervention
(cases per 10,000 persons per annum)
Intervention
Intensity of
control effort 5 years 10 years 20 years 5 years 10 years 20 years
S Low 9.4 7.4 6.3 3.3 2.6 2.1
Medium 3.9 3.9 3.9 1.3 1.3 1.3
High 1.8 1.8 1.8 0.6 0.6 0.6
A Low 13.5 13.6 13.6 4.6 4.6 4.6
Medium 12.8 13.0 13.1 4.3 4.4 4.4
High 12.8 12.3 12.5 4.3 4.2 4.2
TR Low 13.6 12.6 9.1 4.6 4.3 3.1
Medium 13.4 11.9 6.8 4.6 4.1 2.4
High 12.8 9.7 4.5 4.4 3.4 1.6
S + A Low 9.1 7.2 6.2 3.2 2.5 2.1
Medium 3.1 3.6 3.6 1.1 1.2 1.2
High 1.4 1.6 1.7 0.5 0.5 0.6
S + TR Low 9.1 6.4 3.1 3.2 2.2 1.1
Medium 3.4 2.6 0.6 1.2 0.9 0.2
High 0.6 0.3 0.2 0.4 0.1 0.1
A + TR Low 13.6 12.6 9.1 4.6 4.3 3.1
Medium 13.4 11.6 6.2 4.6 4.0 2.2
High 12.8 9.1 4.1 4.4 3.2 1.4
S + A + TR Low 9.1 6.4 3.1 3.2 2.2 1.1
Medium 3.4 1.2 0.5 1.2 0.9 0.2
Hi 1.2 0.1 0.1 0.4 0.1 0.1
None 14.0 14.0 14.0 4.7 4.7 4.7
S, surgery; A, antibiotics; TR, transmission reduction; TT, trachomatous trichiasis; CO, corneal opacities.
TABLE 1. Trachoma treatment schedules implemented at three individual control interventions and three intensity levels. Each set of
three simulated annual MDA rounds, for medium and high intensities of the antibiotic intervention, are conducted immediately
following the previous three annual rounds.
Intensity of control effort
Intervention Definition of intervention Low Medium High
Surgery TT case backlog clearance time 10 years 5 years 2 years
Antibiotics Annual MDA rounds at
mean 86% coverage
3 (3 rounds followed
by population prevalence
review is recommended
by WHO)
3 + 3 annual rounds
(also at mean 86%
annual coverage)
3 + 3 + 3 annual rounds
(also at mean 86%
annual coverage)
Transmission
reduction
Reduction of transmission
rate per year (until final
transmission rate is 1/10
of its initial value)
3% 4.5% 9%
MDA, mass drug administration; TT, trachomatous trichiasis; WHO, World Health Organization.
Impact of Treatment on Trachoma Sequelae 397
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prevalence, respectively21) is because, in a steady
state, the infection process is not sufficient to generate
new cases of TT and CO in these lower endemic
settings. However, it does appear to be the case that
several currently low-endemicity regions were ini-
tially high-endemicity and, therefore, a higher preva-
lence than expected of disease sequelae may be found
in these settings. Our intervention simulations mimic
this effect by considering ‘‘transmission reduction’’
interventions on the high-endemicity population,
which rapidly reduce infection but leave previously
developed TS, TT and CO, and allow for the continu-
ous generation of CO cases, which do not require
further infection.
RESULTS
Prevalence of Disease Sequelae Following
Implementation of the Components of the
Full Intervention Strategy Individually and in
Combination
Figure 2 illustrates the impact on the age-dependent
prevalence of disease sequelae of the three
interventions selected from the full set described in
Tables 1 and 2. The first of these (Figure 2A) shows
that the impact on prevalence of sustained antibiotic
intervention alone, acting at a high intensity of control
effort (three annual rounds of MDA followed by a
further two sets of three annual rounds) is such that
there is little change in prevalence; the transmission
rate is too high and infection rebounds very rapidly
following MDA, which in turn sustains a steady
number of new cases of TS, TT and CO.
The combination of antibiotic MDA and ‘‘transmis-
sion reduction’’ (Figure 2B), each at a high level of
intensity, reduces the transmission rate to 10% of its
initial value in 10 years and effectively transforms the
transmission setting from a level of high- to low-
endemicity. However, the impact of this intervention
takes years to become evident in the prevalence of
scarring sequelae, and it is only 20 years after the
cessation of the intervention that significant changes
in the prevalence pattern are seen. However, when the
entire strategy is deployed (Figure 2C), the prevalence
of TT can be reduced to 0% in 20 years because
surgery for trichiasis is also intensely implemented.
The incidence of CO is also more rapidly reduced by
the full strategy, but there is a delay in its reduction
FIGURE 2. Response of trachoma disease sequelae prevalence to treatment. Simulated age-dependent prevalence of disease sequelae
(trachomatous scarring [TS], dark blue lines [left]; trachomatous trichiasis [TT], light blue lines [middle]; and corneal opacities [CO],
green lines [right]), in a high-endemicity trachoma setting at baseline, following three treatment schedules; (A) antibiotics (A) only, at
high intensity; (B) A+ transmission reduction (TR) both at high intensity; (C) surgery (S) + A + TR all at high intensity. In each plot, the
thicker lines represent baseline prevalence over age and each subsequent lower curve is plotted at 5-year intervals such that the
bottom-most curves represent the prevalence levels 20 years after baseline. In (A), the markers indicate the prevalence values of TS,
TT, and CO observed in Kongwa, Tanzania9 with error bars representing 95% confidence intervals of the collected dataset.
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due to the slow disappearance (via any-cause mortal-
ity) of those cases of CO that arose prior to the
intervention. Other than the surgery-induced large
decline in TT prevalence shown in Figure 2C, the
declines seen in sequelae prevalence levels are largely
demographic; they occur as a consequence of natural
mortality in populations with TS, TT and CO, since
surgery is the only effective measure available to
reverse progress toward more severe disease among
individuals with TT.
Prevalence and Incidence of Disease
Sequelae on Implementation of
Interventions
Figure 3 illustrates the population prevalence of TT
and incidence of CO over time during and following
the three selected treatment schedules that we used to
project the prevalence profiles in Figure 2. The small
drop in these measures for the ‘‘antibiotic only’’
schedule (solid lines, Figure 3A and B), in which nine
annual MDA rounds are administered, creates a small
but long-lasting decrease in both disease levels due to
the decline in the number of new cases generated
through infection, as well as the damage due to TT.
This benefit of antibiotic administration should not
be underemphasized since it will result in fewer
cases of blindness and severe discomfort, but there
will be a steady tendency to rebound (to pre-inter-
vention levels) of both disease sequelae. The time
course of the incidence of CO and the prevalence of
TT following the initiation of the A + ‘‘transmission
reduction’’ intervention (dashed line, Figure 3A
and B) is much more persistently downward, but it
is not until surgery is added to the combination of
interventions (dot-dashed line, Figure 3A and B) that
the prevalence of TT and incidence of CO is brought
down sufficiently quickly to make achieving the
GET2020 program goals by the year 2020 feasible.
Incidence of CO, Prevalence of TT and the
GET2020 Program Goals
Results from a comprehensive exploration of the
impact of each of the components of the full inter-
vention strategy, individually and together, are given
in Table 2. The outcome measures included in the
table are those associated with the GET2020 program
goals, namely the incidence of CO (persons per 10,000
per annum), and the prevalence of TT (as a percent-
age) 5, 10 and 20 years following the beginning of the
interventions. Here, it can clearly be seen which
control strategies employed alone or together result in
the achievement of the GET2020 program goals. The
strategy components and combinations that succeed
are dark-shaded and those that bring sequelae levels
very close to the goal (here quantified as a CO
incidence of two persons per 10,000 per annum, or TT
prevalence of two persons per 1000) are light-shaded.
Several general trends can be seen; first, the inclusion
of greater numbers of the intervention components
leads more readily to the accomplishment of the
(current or former) GET2020 program goals; second,
the implementation of surgery is immensely import-
ant and, indeed, surgery is the intervention compo-
nent that most surely results in the achievement of the
sequelae-related goals when implemented alone; third,
the TT goal is not quite as readily achieved as the CO
goal, which is a consequence of the time delay in the
drop in prevalence compared with incidence, result-
ing in the achievement of this goal taking longer than
the year 2020 target.
DISCUSSION
In this paper, we investigated the impact on TS and
blinding disease sequelae of the components of a
multi-pronged intervention strategy implemented at
FIGURE 3. Response of trachomatous trichiasis (TT) prevalence and corneal opacity (CO) incidence to treatment. Trend in: (A) prevalence
of TT, and (B) incidence of CO through time following three treatment schedules initiated at 0 years (black arrow). From the uppermost to
the bottom curve, the population is subjected to mass drug administration (MDA) at high intensity (dark solid line), MDA + transmission
reduction (TR) both at high intensity (upper dark dotted line), and MDA + TR + surgery (S), all at high intensity (lower light dotted line).
The horizontal dotted line represents the relevant threshold for the Global Elimination of blinding Trachoma by 2020 (GET2020) program
goals (a level of one case of CO per 10,000 persons per annum, and a prevalence of one case of TT per 1000 persons).
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various degrees of control effort intensity, individu-
ally and together. In the absence of data on the long-
term impact of treatment on these sequelae, mathem-
atical models may provide helpful projections of
treatment impact to help assess the feasibility of
reaching the year 2020 goals.
Referring to the three questions we sought to
answer at the beginning of this article, we find that:
(1) Increased intensity of all interventions will more
quickly positively impact ocular disease incidence
and prevalence levels. Increased levels of surgery will
most surely impact the indictors included in the
GET2020 program goals. However, surgery alone is a
stopgap measure, until transmission can be reduced
and, once reduced, the impact on ocular disease of
MDA is also enhanced. (2) The GET2020 program
goals are still achievable in theory if all interventions
are implemented simultaneously (and with the pro-
viso that our ‘‘transmission reduction’’ intervention
may not be easily implemented on the ground). (3)
Under current intervention regimes and in high-
transmission settings (i.e. in hyperendemic commu-
nities) the GET2020 program goals may be difficult to
achieve sooner than around 20 years from now.
A few studies have observed declines in prevalence
of infection and disease that have occurred either
disproportionately with respect to the antibiotic
treatment administered,22,23 or even entirely without
antibiotics.24 The elimination of ocular chlamydial
infection from many countries in which it was
previously endemic preceded the widespread use of
antibiotic treatment for trachoma and was probably
related to economic and infrastructural improve-
ment.25 The facial cleanliness (F) and environmental
improvement (E) components of the SAFE strategy
seek to lower the level of bacterial transmission so that
antibiotic treatment has a greater impact, or the
infection is driven to elimination without the need
for antibiotics. We have shown that in high-
endemicity settings, infection may rebound too
quickly to give rise to a sustained reduction of the
incidence of disease sequelae when antibiotic treat-
ment is administered alone. In such cases, the S, F and
E components of the SAFE strategy would appear to
be crucial and could result in the local elimination of
infection as well as a rapid reduction in the number of
new cases of CO and blindness.25 Our model does not
explicitly include the F&E intervention, since little is
known of its effectiveness in reducing population
infection and disease. However, a recent meta-ana-
lysis of the available data for WASH interventions and
their preventative impact on trachoma has found that
a clean face is highly associated across many studies
with the absence of TF.26 Quantitative estimates of risk
reductions such as these may be translated into
changes in model parameters in future work that
explicitly examines the F&E intervention. Background
secular trends (e.g. non-programmatic environmental
improvements, washing practices, and fly density
reduction) would be similarly modeled.
The main GET2020 program goal, namely, the
elimination of incident blindness as a result of
trachoma by 2020,1,8,19 is linked, in the model, to the
interruption of the transmission of infection and the
slowing down or stopping of progress along the
ladder of infection, although we represent the path
from TT to CO as a process with constant rate without
the need for further infection. We find that the
incidence of CO drops by around 20% of its initial
value following nine annual MDA rounds (Figure 3B),
and it is only after the transmission rate has been
reduced very substantially and surgery for TT is
intensely provided that these sequelae are no longer
incident.
Model Limitations
The model implemented here is limited by its simpli-
city. First, it is deterministic, which precludes the
possibility of investigating infection elimination,
second, it assumes that contact between individuals
is homogeneous between sexes, although not over
ages, third, it does not take into account differences in
transmission within and between households, a het-
erogeneity in transmission that has been shown to be
important in trachoma epidemiology,27 an issue
investigated in a recent modeling study,28 and
fourth, the ‘‘transmission reduction’’ intervention
was modeled as a linear decline in transmission and
is not currently calibrated to published effectiveness
levels, which remain very uncertain and are yet to be
evaluated in highly-controlled study settings. This
uncertainty is very important, since estimates of the
time to achieve elimination under ‘‘transmission
reduction’’ are strongly dependent on its effective-
ness. We have accounted for this by performing
time-to-elimination calculations over a range of
‘‘transmission reduction’’ effectiveness values, to
allow readers to gain insight into the change in
likelihood of elimination with increases in intensity of
each intervention. The simplicity of the current model
therefore limits investigations into the effects of
targeted treatment (e.g. to children, or to households
in which there is at least one case of active disease).
Our simplified representation of trachoma natural
history and, particularly, the abrupt threshold number
of prior infections necessary to reach the disease states
TS and TT, might also be modified in future work by
associating a probability with the development of TS
and TT over a range of infection levels, or by using a
disease sequelae model closer to those used for
helminth-induced disease, in which the population
moves towards severe disease states, with a rate
depending on the number of prior infections.29 Fifth,
the observed persistence of active disease following
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the elimination of infection11,30 underscores the idea
that repeat infection does not drive disease alone, and
forecasting efforts will need to account for this.
Finally, our results were obtained by fitting our
model to data from Kongwa district, Tanzania, and
our conclusions would be more robust if, in future
work, we used the model fit to other data sets.
Policy Implications
The policy implications of the tabular summary of all
intervention permutations (Table 2) are clear; for
communities with high infection prevalence at baseline,
a combination of efforts is needed to bring down the
prevalence and incidence of sequelae sustainably to
achieve the GET2020 program goals. Table 2 highlights
the importance of surgery to create a pathway to
achieving the 2020 goals. Previous studies have shown
that MDA is beneficial for the clearance of inflammation
and prevention of subsequent scarring, but we show
here that it needs to be coupled with sustainable
reductions in transmission (most likely through envir-
onmental and water and sanitation improvement)
before the elimination of blinding disease due to
trachoma can be considered realistically. For medium-
and low-endemicity communities at baseline, the model
generates far fewer new cases of TT and CO, and a
combination of surgery to clear the backlog of TT cases
and antibiotics to clear infection may be enough to
eliminate blindness. This conclusion is also implied by
Table 2, since the aim of a ‘‘transmission reduction’’
campaign is to change permanently the conditions
propitious for a highly-endemic setting into those of a
low-endemic (or non-endemic) setting. Our model
suggests that antibiotics can reduce trachoma in
communities such as Kongwa, but a secular trend will
be necessary to keep it from returning. Summaries of the
potential impact of interventions such as those provided
in Table 2, may prove very useful for program managers
to optimize their decisions at the beginning or during
interventions, particularly in resource-constrained set-
tings, where careful consideration needs to be given to
those interventions or combinations thereof which will
provide the best value for money. Similar model-based
analyses have allowed the systematic exploration of
combining existing malaria control interventions (i.e. in
the absence of an effective vaccine)31 which is now a
cornerstone of the debate on malaria elimination. Such
summaries of the paths to elimination will need to be
accompanied by health-economic analyses in future
work to obtain greater clarity of the relative cost-benefits
and cost-effectiveness of the strategies, and therefore the
overall effort necessary to implement each of the
interventions simulated here. In addition to studies
conducting scenario analyses, important next steps
would be to fit mathematical models to post-interven-
tion longitudinal data, once sufficient data have been
collected, as well as extend the complexity of models to
allow for population immigration and the inclusion of
regions of differing endemicity (as have Lietman and
colleagues10).
In conclusion, trachoma disease sequelae will con-
tinue to develop in the years to come, particularly in
highly endemic regions, and so there is a need for the
ongoing provision of services, such as surgery for
trichiasis, even when the prevalence of active disease is
dropping. Evidence for the effectiveness of the F&E
intervention is needed to allow transmission reduction
to be achieved with greater certainty than is currently
possible. The GET2020 program goals may yet be
achievable, but unless infection can be eliminated with
mass antibiotics, then a substantial and sustained effort
will be required to provide surgery and continue
implementing all components of the SAFE strategy.
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